NCT04581343View on ClinicalTrials.gov

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

November 2, 2022

Study Completion Date

February 27, 2023

Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine

Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion

Trial Locations (2)

10016

New York University, New York

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Pancreatic Cancer Action Network

OTHER